IPO Symbol - Search News

LNG exporter Venture Global slashes IPO price range

Venture Global LNG raises $1.75 billion after pricing US IPO

Venture Global LNG has raised $1.75 billion after pricing its U.S. initial public offering within range, the second-largest exporter of liquefied natural gas in the United States said on Thursday. The company priced its offering of 70 million shares at $25 each,

MarketWatch on MSN · 1d

LNG exporter Venture Global slashes IPO price range despite President Trump’s pro-energy push

Venture Global is now seeking a more reasonable valuation of about $65 billion, versus earlier plans for about $110 billion.

CNBC on MSN · 1h

LNG pure-play Venture Global's IPO tests appetite for energy stocks under Trump administration

"The Trump administration has made very clear they support growing LNG exports," Venture CEO Mike Sable told CNBC in an interview Friday.

Reuters · 15h

LNG exporter Venture Global raises $1.75 bln in US IPO

Liquefied natural gas exporter Venture Global said on Thursday it had raised $1.75 billion, marking the first big initial public offering of President Donald Trump's second term as investors bet on his plan to boost U.

Seeking Alpha on MSN · 1d

LNG exporter Venture Global slashes IPO valuation target by $45B after investors balk

Liquefied natural gas producer Venture Global slashed the proposed range for its IPO on Wednesday, lowering the valuation it sought to ~$65B from the initial target of $110B at the top of the previous range.

Takeda, Ascentage Pharma and IPO

Bloomberg L.P. · 1h

Ascentage Pharma’s US Shares Climb After $126 Million IPO

Shares of Ascentage Pharma Group International rose as much as 4% in the Chinese biopharmaceutical company’s US trading debut after pricing its $126.4 million initial public offering at a discount to its Asian stock.

Seeking Alpha on MSN · 1h

Takeda-backed Ascentage Pharma prices $126M U.S. IPO

Ascentage Pharma Group (AAPG) (AAPGV) (OTCPK:ASPHF), which is backed by Takeda (NYSE:TAK), has priced a $126M U.S. initial public offering. The China-based drug developer priced 7.33M shares at $17.25 per share,

Reuters on MSN · 17h

Takeda-backed Ascentage Pharma aims to raise $126 million in US IPO

Ascentage Pharma said on Thursday it aims to raise $126.4 million in an initial public offering in the United States, becoming the first sizeable Chinese firm to seek a listing in the U.S. this year.

LNG exporter Venture Global cuts target valuation for US IPO to $65.3 billion

Venture Global LNG on Wednesday slashed the valuation it sought from a U.S. initial public offering to $65.33 billion, ...

BioPharma Dive3d

Sionna, Odyssey join queue of biotechs testing investors’ IPO interest

The startups are the fourth and fifth drugmakers to file for initial stock sales since late December — the most IPO activity ...

MarketWatch6d

Sailpoint Files for IPO

The company plans to list its shares on the Nasdaq Global Select Market under the symbol SAIL. The company expects to use the proceeds of the IPO to reduce its indebtedness and increase its ...

Results that may be inaccessible to you are currently showing.

Hide inaccessible results

LNG exporter Venture Global slashes IPO price range

Takeda, Ascentage Pharma and IPO

Trending now